Rosacea is a prevalent chronic cutaneous disorder that often presents relapsing course and is challenging to treat. It is frequently necessary to use off-label treatments to achieve satisfactory results.We report the use of a single session of medium depth peel with Jessner''''''''s solution and 35% trichloroacetic acid in fifteen patients, which achieved good clinical outcomes and histopathological improvement.The use of medium-depth peels must, therefore, be considered a therapeutic option for the treatment of rosacea.

Keywords: ROSACEA, CHEMEXFOLIATION, TRICHLOROACETIC ACID, RESORCINOLS, SALICYLIC ACID

Introduction: Rosacea is a chronic facial condition characterized by erythema, edema, telangiectasias, papules and possibly pustules and nodules. There are four subtypes: erythematous-telangiectatic rosacea (I), papulopustular rosacea (II), phymatous rosacea (III) and ocular rosacea (IV). Its pathogenesis is multifactorial, and the treatments, diverse.
Objective: To demonstrate the effect of botulinum toxin in the improvement of flushing and erythema in patients with erythematous-telangiectatic rosacea.
Methods: Six patients with Subtype I rosacea were selected in the Dermatology Department’s outpatient clinic of a university medical service. The patients received applications of botulinum toxin type A (dilution of 100 units to 5 ml of saline solution), with intradermal injections of 0.2 to 0.5 units per point in the affected region. Evaluations were carried out after one, two, three and six consecutive months.
Results: There was improvement of the facial erythema and flushing during the three months following the application, with symptoms returning around the sixth month after the treatment, in line with the estimated duration of toxin effectiveness.
Conclusions: There was improvement of the patients' symptoms and satisfaction, and it was deemed a treatment of easy application, associated with a low index of adverse effects and prolonged duration of outcomes.

Keywords: Botulinum Toxins, Type A; Erythema; Quality of Life; Rosacea

Rosacea is a common chronic skin disease that has several clinical manifestations, with erythema and inflammation being predominant characteristics. Its presence is associated with psychosocial impact on patients' lives. Although there are several options for topical and systemic treatments, it is known that only the inflammation is treated and that the erythema persists in most cases. More recently, there have been some publications describing the treatment of rosacea with botulinum toxin associated with good results. In this manner, the authors sought to evaluate the action of botulinum toxin in the treatment of rosacea that is persistent and refractory to various clinical treatments.

Keywords: Rosacea; Botulinum Toxins; Therapeutics

Rhinophyma is a disfiguring and progressive disease of the nose with high prevalence. Despite being considered a benign condition, many patients have sought curative treatments due to aesthetic deformity and social stigmatization. There are several surgical techniques described in the treatment of this disease. This report aims to present a case that required an unusual therapeutic approach for the treatment of rhinophyma, given the patient's multiple comorbidities. The procedure was performed with no complications in the intra and postoperative period. The patient maintains an outpatient follow-up with a good long-term aesthetic result.

Keywords: Dermatologic Surgical Procedures; Rhinophyma; Rosacea

INTRODUCTION: Rosacea is a chronic inflammatory skin disease. The intradermal application of botulinum toxin (BT) has been studied as a therapeutic option for patients who struggle to manage flushing and/or persistent facial erythema. There is no standard protocol for TB application in rosacea.
OBJECTIVE: To evaluate the effectiveness of botulinum toxin application on erythematotelangiectatic rosacea.
METHODS: Pilot study with case series. We applied intradermal TB in 10 patients with a diagnosis of rosacea and symptoms of persistent erythema and/or facial flushing. Patients received 10 to 15 injections per hemiface (1 unit of onabotulinum TB per injection) and 0 to 5 injections in the nasal region, totaling 25 to 35 units per patient.
RESULTS: Seventy-five percent of the patients presented a reduction in flush and erythema intensity. The follow-up time was three months, and no serious adverse events were observed.
CONCLUSIONS: The therapeutic arsenal to control erythema and facial flushing of rosacea, especially refractory to the usual treatment, should consider the intradermal application of TB type A.

Keywords: Erythema; Rosacea; Flushing; Botulinum toxins